Design, synthesis, and optimization of Honokiol-Piperazine derivatives as lung-enriched agents against MRSA pneumonia
Ruixue Zhang1, Yifan Zhong2, Hongzhi Gong1
1School of Pharmaceutical Sciences, Chongqing Key Laboratory of Natural Product Synthesis and Drug Research, Chongqing University, No. 55 Daxuecheng South Rd., Shapingba, Chongqing 401331, PR China.
Abstract:
Methicillin-resistant Staphylococcus aureus (MRSA) causes severe bacterial pneumonia; current therapies (e.g., vancomycin) suffer from poor pulmonary bioavailability and dose-limiting safety concerns, demanding precision lung-enriched agents. However, small-molecule lung-enriched antibacterials are relatively rare. Honokiol (HNK), a natural phenolic compound with broad pharmacological activities but moderate antibacterial potency and limited tissue selectivity, was selected as the scaffold. We integrated a piperazine moiety into HNK and synthesized a series of HNK-piperazine derivatives. Among them, 13f showed potent activity primarily against Gram-positive bacteria, including MRSA (MIC: 2-4 μM; 16-32-fold more potent than HNK) together with preferential lung exposure. 13f exhibited rapid bactericidal activity and showed minimal MIC shift under sub-MIC selection over 31 serial passages (MICₙ/MIC₀ = 1-2), whereas ciprofloxacin displayed a 256-fold increase over the same period; it also attenuated staphyloxanthin production and reduced biofilm biomass. Mechanistic assays suggested time- and concentration-dependent membrane-associated effects, as reflected by permeability/depolarization readouts, nucleic acid/protein leakage, SEM imaging, and complementary MD analyses, with more pronounced effects at higher exposures. Pharmacokinetic and biodistribution analyses revealed a 13-fold longer half-life and a 147.92-fold higher lung AUC for 13f than for HNK. In a murine MRSA pneumonia model, 13f substantially reduced pulmonary bacterial burden and showed in vivo activity in the same overall range as vancomycin under the tested dosing regimen. No obvious histopathological alterations were observed under the tested short-term conditions. Overall, this work demonstrated a small-molecule approach to combine lung enrichment with potent anti-MRSA activity, supporting the further preclinical evaluation of 13f for MRSA pneumonia.
Insights
Researchers developed a novel compound, 13f, derived from honokiol (HNK), demonstrating potent activity against Methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. This new agent offers enhanced lung exposure and reduced resistance development compared to existing treatments.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Infectious Diseases
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) causes severe pneumonia, with current therapies like vancomycin exhibiting limited lung penetration and safety concerns.
- The development of novel, lung-enriched antibacterial agents is crucial for effective MRSA pneumonia treatment.
- Small-molecule antibacterials with preferential lung accumulation are scarce.
Purpose of the Study:
- To synthesize and evaluate novel honokiol (HNK) derivatives for enhanced anti-MRSA activity and preferential lung accumulation.
- To investigate the antibacterial mechanisms and in vivo efficacy of the lead compound in a preclinical MRSA pneumonia model.
Main Methods:
- Synthesis of HNK-piperazine derivatives.
- In vitro antibacterial assays, including minimum inhibitory concentration (MIC) determination and serial passage studies.
- Mechanistic studies involving membrane permeability, depolarization, and leakage assays.
- Pharmacokinetic and biodistribution analyses in mice.
- In vivo efficacy evaluation in a murine MRSA pneumonia model.
Main Results:
- Compound 13f displayed potent activity against MRSA (16-32 fold more potent than HNK) with preferential lung exposure.
- 13f exhibited rapid bactericidal activity and significantly lower resistance development compared to ciprofloxacin.
- Mechanistic studies indicated time- and concentration-dependent membrane-associated effects.
- Pharmacokinetic analysis showed a 13-fold longer half-life and a 147.92-fold higher lung area under the curve (AUC) for 13f compared to HNK.
- In vivo, 13f effectively reduced pulmonary bacterial burden in a murine MRSA pneumonia model.
Conclusions:
- The HNK-piperazine derivative 13f represents a promising small-molecule approach for developing lung-enriched antibacterials against MRSA.
- 13f demonstrates potent anti-MRSA activity, favorable pharmacokinetic properties including lung enrichment, and reduced resistance potential.
- Further preclinical evaluation of 13f is warranted for the treatment of MRSA pneumonia.
More Related Videos
03:22Author Spotlight: Advancing Pathogen Detection and Disease Assessment in Real-Time Using M-ROSE
Published on: March 1, 2024
10:26P. aeruginosa Infected 3D Co-Culture of Bronchial Epithelial Cells and Macrophages at Air-Liquid Interface for Preclinical Evaluation of Anti-Infectives
Published on: June 15, 2020
Related Concept Videos
01:28Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
01:27Combined Effects of Drugs: Synergism
Such synergistic combinations...
00:57Antibiotic Selection